AstraZeneca receives double EU recommendation for cancer drug

Lynparza is recommended for marketing authorisation for ovarian and prostate cancer, while Tagrisso showed positive results in late-stage trials for lung cancer

AstraZeneca - AstraZeneca receives double EU recommendation for cancer drug

AstraZeneca PLC (LON:AZN) revealed it has received a double recommendation in the European Union for its cancer drug Lynparza.

The FTSE 100-listed group[ said the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the candidate for marketing authorisation for both HRD-positive advanced ovarian cancer and in advanced prostate cancer with a BRCA mutation.

READ: AstraZeneca resumes coronavirus vaccine trials in the UK

In the case of ovarian cancer, the drug was advised as a first-line maintenance treatment with bevacizumab after late-stage trials showed the combination reduced the risk of disease progression or death by 67%.

Ovarian cancer is the fifth most common cause of cancer death in Europe and the five-year survival rate is 45%, in part because women are often diagnosed with advanced disease.

Prostate cancer is the second-most common type of cancer in men, with an estimated 1.3mln new patients diagnosed worldwide in 2018, while 12% of patients have a BRCA mutation.

Lynparza is currently approved in several countries for certain types of ovarian, breast and pancreatic tumours.

In a separate announcement, the pharma giant said that another cancer treatment, Tagrisso has shown a clinically meaningful improvement in patients with early-stage non-small-cell lung cancer (NSCLC) after the tumour had been removed completely.

In the phase III trials, 11% of patients treated with Tagrisso had recurrence events or deaths compared to 46% on placebo.

Tagrisso is currently approved as a first-line treatment for other types of NSCLC in several countries but nowhere as an adjuvant, which is aimed at stopping the tumour coming back after the primary treatment.

Quick facts: AstraZeneca

Price: 8183 GBX

Market: LSE
Market Cap: £107.48 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ferro-Alloy Resources 'extremely active' after first commercial sale of...

Ferro-Alloy Resources Ltd's (LON:FAR) Nick Bridgen talks to Proactive London about their first commercial production and sale of calcium molybdate. Bridgen explains what the product is used for, the production of ferromolybdenum, molybdenum-containing alloys, ceramics and direct alloying of...

1 hour, 11 minutes ago

2 min read